Ephrin A1-targeted nanoshells for photothermal ablation of prostate cancer cells

International Journal of Nanomedicine

Volumn 3, Issue 3, 2008, Pages 351-358

  Gobin, Andre M ^a   Moon, James J ^a   West, Jennifer L ^a  

^a Rice University   (United States)

Author keywords

Nanoshell; Near infrared; Photothermal treatment; Prostate cancer

Indexed keywords

EPHRIN A1; EPHRIN A2; NANOSHELL; EPHRIN RECEPTOR; NANOMATERIAL;

ARTICLE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL ADHESION; CELL SPECIFICITY; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPERTHERMIC THERAPY; LASER; MALE; PHOTOSENSITIVITY; PHOTOTHERAPY; PROSTATE CANCER; THERMAL STIMULATION; TREATMENT RESPONSE; CELL SURVIVAL; DRUG DELIVERY SYSTEM; INFRARED RADIATION; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PROSTATE TUMOR; RADIATION EXPOSURE; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; HUMANS; HYPERTHERMIA, INDUCED; INFRARED RAYS; MALE; NANOSTRUCTURES; PHOTOTHERAPY; PROSTATIC NEOPLASMS; RECEPTORS, EPH FAMILY;

EID: 58149277085     PISSN: 11769114     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Averitt RD, Westcott SL, Halas NJ. 1999. Linear optical properties of gold nanoshells. J Optic Soc Am B, 16:1824-32.
2. Brantley-Sieders D, Schmidt S, Parker M, et al. 2004. Eph receptor tyrosine kinases in tumor and tumor microenvironment. Curr Pharm Des, 10:3431-42.
3. Brantley DM, Cheng N, Thompson EJ, et al. 2002. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene, 21:7011-26.
4. Carles-Kinch K, Kilpatrick KE, Stewart JC, et al. 2002. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res, 62:2840-7.
5. Connor EE, Mwamuka J, Gole A, et al. 2005. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small, 1:325-7.
6. Duff DG, Baiker A, Edwards PP. 1993. A new hydrosol of gold clusters. 1. Formation and particle size variation. Langmuir, 9:2301-9.
7. Fang WB, Brantley-Sieders DM, Parker MA, et al. 2005. A. kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene, 24:7859-68.
8. Fox BP, Kandpal RP. 2004. Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. Biochem Biophys Res Commun, 318:882-92.
9. Fox BP, Tabone CJ, Kandpal RP. 2006. Potential clinical relevance of Eph receptors and ephrin ligands expressed in prostate carcinoma cell lines. Biochem Biophys Res Commun, 342:1263-72.
10. Gobin AM, Lee MH, Halas NJ, et al. 2007. Near-infrared resonant nanoshells for combined optical imaging and photothermal cancer therapy. Nano Lett, 7:1929-34.
11. Hess AR, Seftor EA, Gardner LM, et al. 2001. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res, 61:3250-5.
12. Hirsch LR, Jackson JB, Lee A, et al. 2003. A whole blood immunoassay using gold nanoshells. Anal Chem, 75:2377-81.
13. Ireton RC, Chen J. 2005. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr Cancer Drug Targets, 5:149-57.
14. Kinch MS, Moore MB, Harpole DH, Jr. 2003. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res, 9:613-18.
15. Loo C, Hirsch L, Lee M-H, et al. 2005a. Gold nanoshell bioconjugates for molecular imaging in living cells. Opt Lett, 30:1012-14.
16. Loo C, Lowery A, Halas N, et al. 2005b. Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett, 5:709-11.
17. Lowery AR, Gobin AM, Day ES, et al. 2006. Immunonanoshells for targeted photothermal ablation of tumor cells. Int J Nanomed, 1:149-54.
18. Marston DJ, Dickinson S, Nobes CD. 2003. Rac-dependent transendocytosis of ephrinBs regulates Eph-ephrin contact repulsion. Nat Cell Biol, 5:879-88.
19. Miao H, Burnett E, Kinch M, et al. 2000. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat Cell Biol, 2:62-9.
20. O'Neal DP, Hirsch LR, Halas NJ, et al. 2004. Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett, 209:171-6.
21. Oldenburg SJ, Averitt RD, Westcott SL, et al. 1998. Nanoengineering of optical resonances. Ch Phys Lett, 288:243-7.
22. Poliakov A, Cotrina M, Wilkinson DG. 2004. Diverse roles of eph receptors and ephrins in the regulation of cell migration and tissue assembly. Dev Cell, 7:465-80.
23. Surawska H, Ma PC, Salgia R. 2004. The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev, 15:419-33.
24. Walker-Daniels J, Coffman K, Azimi M, et al. 1999. Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate, 41:275-80.
25. Weissleder R. 2001. A clearer vision for in vivo imaging. Nat Biotechnol, 19:316-7.
26. Zelinski DP, Zantek ND, Stewart JC, et al. 2001. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res, 61:2301-6.
27. Zeng G, Hu Z, Kinch MS, et al. 2003. High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol, 163:2271-6.